HealthTech Company Flatiron Health is collaborating with NRG Oncology, the clinical research consortium of the National Cancer Institute’s National Clinical Trial Network, which has over 1,300 research sites around the world, to deploy the Flatiron clinical pipe in multicenter NRG clinical trials.
Flatiron Clinical Pipe is an Electronic Data Capture (EDC) connector from an Electronic Data Capture (EDC) connector that aims to improve the efficiency of clinical research data entry and reduce time and effort.
The purpose of the collaboration is to include NCTN-sponsored studies by applying Flatiron’s EHR-EDC technology to reduce the burden on NRG clinical trial site teams, streamline data management, and accelerate research timelines.
NRG and Flatiron conduct correlation studies to assess the efficiency of Flatiron clinical pipe use compared to traditional data entry methods.
“Working with NRG Oncology, a leading research consortium within the National Clinical Trials Network, is an incredible opportunity to create new trial experiences, unlock higher data quality and unlock more efficient data collection through the Flatiron Clinical Pipe,” says Alex Deyle, general manager of clinical research at Flatiron Health.
“By putting cutting-edge technology into the hands of more research teams, Flatiron and NRG will strengthen their continued efforts to improve efficiency, reduce time and effort in research data capture, and ultimately accelerate evidence generation and improvement in the care of cancer patients.”
Healthcare AI Platform Notably, it has signed a multi-year partnership with CityMD, a New York and New Jersey emergency health care provider.
Through partnerships, CityMD leverages prominent AI and automation technologies across more than 180 sites with the aim of improving patient access, promoting operational efficiency, and reducing the administrative burden associated with walk-in care.
Alliance will showcase its attention-grabbing AI platform and intelligent agents that drive automation across multiple use cases, including emergency care scheduling, messaging, patient registration, intakes, and payments.
“While emergency care is a key gateway to a healthcare system of millions, patients often encounter unnecessary delays and barriers to timely care,” Pranay Kapadia, CEO of the statement, said in a statement.
“We are tackling these challenges head-on by providing CityMD with renowned AI-powered automation. Our technology streamlines all appointments, registrations and follow-ups, ensuring that our healthcare teams operate more efficiently despite staffing.”
Bamboo Health, a real-time care intelligence company, Ohio State will strengthen its prescription drug surveillance system known as the Ohio Automated RX Reporting System (OARRS).
The state hopes to achieve this by adding features Directly to existing workflows This alerts the health care provider if the patient has a prior history of drug overdose.
OD Insights is the latest addition to Bamboo Health’s suite of prescription drug monitoring programs, and aims to improve care coordination, allowing the emergency department to direct high-risk patients to the most relevant treatment options, including access to opioid use disorders and drug therapy to prevent fatal overdose.
According to the company, by seamlessly integrating with OARRS, OD Insights provides timely, appropriate data, supporting clinical decision-making while providing prescription data while maintaining the same protection.
Additionally, providers can closely view patients’ controlled substance use history at points of care to support informed prescribing practices as part of a multidimensional response to the ongoing opioid epidemic.
“The Ohio Pharmacy Board continues to be at the forefront of using technology to address the opioid epidemic,” Bamboo Health’s Chief Commercial Officer, Ross Armstrong, said in a statement.
“We partner with Ohio to implement OD Insights and believe this initiative will serve as a model for other states seeking to reduce harm and increase access to treatment.”
